Department of Hematology, Xiangya Hospital Central South University, Changsha, P.R. China.
Department of Hematology, The Third Xiangya Hospital of the Central South University, Changsha, P.R. China.
J Cell Physiol. 2019 Nov;234(11):20322-20328. doi: 10.1002/jcp.28632. Epub 2019 Apr 4.
The glutamine amino acid transporter solute carrier family 38 member 1 (SLC38A1) is associated with the occurrence and progression of solid tumors. However, it has not yet been assessed in patients with hematologic malignancy. Herein, we investigated SLC38A1 expression and explored its clinical implications in acute myeloid leukemia (AML). The results showed that patients with high SLC38A1 expression had a lower mutation rate of NPM1 gene and higher incidence of adverse-risk karyotype (p = 0.0010 and 0.0051, respectively). Patients with a high level of SLC38A1 expression presented significantly shorter overall survival in whole-cohort, chemotherapy-only, and non-inv(16) AML (p = 0.0049, 0.0247, and 0.0005 respectively). Moreover, both univariate and multivariate analyses showed that high SLC38A1 expression was an independent unfavorable prognostic biomarker for AML (p = 0.0057 and 0.0483, respectively). In summary, our study revealed SLC38A1 as a valuable prognostic and predictive marker for AML. Further, glutamine transporter SLC38A1 might serve as a potential target for the development of novel therapeutic drugs in the treatment of AML.
谷氨酰胺氨基酸转运蛋白溶质载体家族 38 成员 1（SLC38A1）与实体瘤的发生和进展有关。然而，它在血液恶性肿瘤患者中尚未得到评估。在此，我们研究了 SLC38A1 的表达，并探讨了其在急性髓系白血病（AML）中的临床意义。结果表明，SLC38A1 高表达患者的 NPM1 基因突变率较低，不良风险核型的发生率较高（p=0.0010 和 0.0051）。SLC38A1 高表达患者的总生存期在全队列、仅化疗和非 inv（16）AML 中明显缩短（p=0.0049、0.0247 和 0.0005）。此外，单因素和多因素分析均表明，SLC38A1 高表达是 AML 的独立不良预后生物标志物（p=0.0057 和 0.0483）。总之，我们的研究表明 SLC38A1 是 AML 的有价值的预后和预测标志物。此外，谷氨酰胺转运蛋白 SLC38A1 可能成为治疗 AML 的新型治疗药物开发的潜在靶点。
